{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:27:39Z","timestamp":1793831259951,"version":"4.6.1"},"reference-count":141,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Pulmonary hypertension (PH) is a heterogeneous and progressive condition defined by elevated mean pulmonary arterial pressure, classified into 5 groups based on underlying etiology and pathophysiology. Affecting millions worldwide, PH carries a poor prognosis, particularly in pulmonary arterial hypertension (group 1). From a cardiology perspective, advancing PH management is essential given the central role of the pulmonary circulation and right ventricular function in cardiovascular homeostasis. Current management emphasizes accurate diagnosis via right heart catheterization, comprehensive risk stratification using models, and the integration of supportive measures. Pharmacologic strategies are constantly evolving, currently including antiproliferative vascular remodeling therapies. Treatment algorithms now favor early combination therapy and dynamic escalation guided by risk assessment. Advanced and interventional options remain vital for select patients. Long-term care requires multidisciplinary coordination, specialized PH centers, and integration of rehabilitation and palliative support. This review discusses the current evidence of PH management, evidence gaps, and future research directions.<\/jats:p>","DOI":"10.1097\/crd.0000000000001121","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:00:35Z","timestamp":1762923635000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["From Pathways to Patients: Contemporary Approaches to Pulmonary Hypertension"],"prefix":"10.1097","author":[{"given":"Cristian","family":"Castillo-Rodriguez","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan Bueso","family":"Pineda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Soliman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Wanichwecharungruang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varote","family":"Shotelersuk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Patricia","family":"Inggriani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Prater","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithila","family":"Sivakumar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Baca-Soto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texas Tech Health Science Center, Lubbock, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"R1-20251112","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","article-title":"A global view of pulmonary hypertension.","volume":"4","author":"Hoeper","year":"2016","journal-title":"Lancet Respir Med"},{"key":"R2-20251112","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension.","volume":"385","author":"Hassoun","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20251112","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-2600(24)00295-9","article-title":"Global, regional, and national burden of pulmonary arterial hypertension, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"13","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"12 Suppl S","key":"R4-20251112","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/j.jacc.2004.02.029","article-title":"Cellular and molecular pathobiology of pulmonary arterial hypertension.","volume":"43","author":"Humbert","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R5-20251112","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review.","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"key":"R6-20251112","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/jpet.118.252700","article-title":"Therapeutic monoclonal antibody antagonizing endothelin receptor A for pulmonary arterial hypertension.","volume":"370","author":"Zhang","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"R7-20251112","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S2213-2600(24)00072-9","article-title":"Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"12","author":"Frantz","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R8-20251112","doi-asserted-by":"crossref","first-page":"9971","DOI":"10.3390\/ijms24129971","article-title":"Pulmonary hypertension in left heart diseases: pathophysiology, hemodynamic assessment and therapeutic management.","volume":"24","author":"Ltaief","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R9-20251112","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3390\/ijms26020835","article-title":"Pathophysiology of group 3 pulmonary hypertension associated with lung diseases and\/or hypoxia.","volume":"26","author":"Nakamura","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R10-20251112","doi-asserted-by":"crossref","first-page":"160112","DOI":"10.1183\/16000617.0112-2016","article-title":"The pathophysiology of chronic thromboembolic pulmonary hypertension.","volume":"26","author":"Simonneau","year":"2017","journal-title":"Eur Respir Rev"},{"key":"R11-20251112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-023-00486-7","article-title":"Pulmonary hypertension.","volume":"10","author":"Mocumbi","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"R12-20251112","doi-asserted-by":"crossref","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension.","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"key":"R13-20251112","doi-asserted-by":"crossref","first-page":"2102548","DOI":"10.1183\/13993003.02548-2021","article-title":"Echocardiographic probability of pulmonary hypertension: a validation study.","volume":"60","author":"D\u2019Alto","year":"2022","journal-title":"Eur Respir J"},{"key":"R14-20251112","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ahj.2022.05.006","article-title":"Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: a systematic review and meta-analysis.","volume":"250","author":"Hendriks","year":"2022","journal-title":"Am Heart J"},{"key":"R15-20251112","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.chest.2020.08.2069","article-title":"Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL lite 2, for use in patients with pulmonary arterial hypertension.","volume":"159","author":"Benza","year":"2021","journal-title":"Chest"},{"key":"R16-20251112","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.chest.2024.03.018","article-title":"Comparison of contemporary risk scores in all groups of pulmonary hypertension: a pulmonary vascular research institute Godeep meta-registry analysis.","volume":"166","author":"Yogeswaran","year":"2024","journal-title":"Chest"},{"key":"R17-20251112","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG).","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"R18-20251112","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/eurjpc\/zwaa001","article-title":"Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits.","volume":"28","author":"Green","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"R19-20251112","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1750-1172-8-97","article-title":"Pulmonary arterial hypertension.","volume":"8","author":"Montani","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"R20-20251112","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fphar.2011.00021","article-title":"Therapeutic strategies in pulmonary hypertension.","volume":"2","author":"Fuso","year":"2011","journal-title":"Front Pharmacol"},{"key":"R21-20251112","doi-asserted-by":"crossref","first-page":"100579","DOI":"10.1016\/j.blre.2019.05.003","article-title":"Indications and potential pitfalls of anticoagulants in pulmonary hypertension: would DOACs become a better option than VKAs?","volume":"37","author":"Margelidon-Cozzolino","year":"2019","journal-title":"Blood Rev"},{"key":"R22-20251112","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1161\/CIRCULATIONAHA.104.488486","article-title":"Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.","volume":"111","author":"Sitbon","year":"2005","journal-title":"Circulation"},{"key":"R23-20251112","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"R24-20251112","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.3390\/ijms241210206","article-title":"Insights into Endothelin receptors in pulmonary hypertension.","volume":"24","author":"Liu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R25-20251112","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1152\/jappl.1995.79.6.2122","article-title":"Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats.","volume":"79","author":"Chen","year":"1995","journal-title":"J Appl Physiol"},{"key":"R26-20251112","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension.","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"R27-20251112","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension.","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur Respir J"},{"key":"R28-20251112","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.amjcard.2013.04.051","article-title":"Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARIES] study 1 and 2 trials).","volume":"112","author":"Maron","year":"2013","journal-title":"Am J Cardiol"},{"key":"R29-20251112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/jcpt.13481","article-title":"Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: a meta\u2010analysis.","volume":"47","author":"Zhao","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R30-20251112","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehx025","article-title":"SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.","volume":"38","author":"Gali\u00e8","year":"2017","journal-title":"Eur Heart J"},{"key":"R31-20251112","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension.","volume":"32","author":"Wilkins","year":"2008","journal-title":"Eur Respir J"},{"key":"R32-20251112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2017.06.010","article-title":"Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro.","volume":"810","author":"Yamamura","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"R33-20251112","first-page":"CD012621","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension.","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"R34-20251112","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.healun.2016.12.012","article-title":"Comparison of hemodynamic parameters in treatment-na\u00efve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.","volume":"36","author":"Gali\u00e8","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"R35-20251112","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1183\/09031936.00090614","article-title":"Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).","volume":"45","author":"Rubin","year":"2015","journal-title":"Eur Respir J"},{"key":"R36-20251112","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R37-20251112","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension.","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"key":"R38-20251112","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension.","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R39-20251112","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.healun.2019.01.220","article-title":"Treatment with oral treprostinil delays time to clinical worsening in patients with pulmonary arterial hypertension-results from FREEDOM-EV.","volume":"38","author":"Tapson","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"R40-20251112","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.","volume":"30","author":"Benza","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R41-20251112","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R42-20251112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"R43-20251112","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"R44-20251112","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.hrtlng.2023.11.006","article-title":"Efficacy and safety of iloprost in the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis.","volume":"64","author":"Zhou","year":"2024","journal-title":"Heart Lung"},{"key":"R45-20251112","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension.","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"R46-20251112","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension.","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"R48-20251112","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/1061186X.2023.2199351","article-title":"Emerging biologics for the treatment of pulmonary arterial hypertension.","volume":"31","author":"Hye","year":"2023","journal-title":"J Drug Target"},{"key":"R49-20251112","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension.","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"key":"R50-20251112","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension.","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"key":"R51-20251112","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"R52-20251112","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension.","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"R53-20251112","doi-asserted-by":"crossref","first-page":"767002","DOI":"10.3389\/fphar.2021.767002","article-title":"Therapy for pulmonary arterial hypertension: glance on nitric oxide pathway.","volume":"12","author":"Tettey","year":"2021","journal-title":"Front Pharmacol"},{"key":"R54-20251112","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/eurheartj\/ehp297","article-title":"Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).","volume":"30","author":"Gali\u00e8","year":"2009","journal-title":"Eur Heart J"},{"key":"R55-20251112","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.201908-1640OC","article-title":"Combination therapy with oral treprostinil for pulmonary arterial hypertension. A double-blind placebo-controlled clinical trial.","volume":"201","author":"White","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R56-20251112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","article-title":"Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension.","volume":"83","author":"Gr\u00fcnig","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R57-20251112","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1183\/09031936.00116313","article-title":"Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.","volume":"43","author":"Sitbon","year":"2014","journal-title":"Eur Respir J"},{"key":"R58-20251112","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three-versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension.","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R59-20251112","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J"},{"key":"R60-20251112","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1164\/rccm.202107-1622LE","article-title":"Initial triple combination therapy for intermediate-and high-risk pulmonary arterial hypertension: standard of care or still too soon to tell?","volume":"204","author":"Jin","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"R61-20251112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1183\/16000617.00000815","article-title":"Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension.","volume":"24","author":"Jenkins","year":"2015","journal-title":"Eur Respir Rev"},{"key":"R62-20251112","doi-asserted-by":"crossref","first-page":"160111","DOI":"10.1183\/16000617.0111-2016","article-title":"Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension.","volume":"26","author":"Jenkins","year":"2017","journal-title":"Eur Respir Rev"},{"key":"R63-20251112","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1183\/09031936.00058112","article-title":"Surgical treatment of chronic thromboembolic pulmonary hypertension.","volume":"41","author":"Jenkins","year":"2013","journal-title":"Eur Respir J"},{"key":"R64-20251112","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.athoracsur.2017.05.024","article-title":"Symptoms are more useful than echocardiography in patient selection for pulmonary endarterectomy.","volume":"104","author":"Donahoe","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"R65-20251112","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.3390\/jcm11236976","article-title":"Pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a systematic review of the most updated literature.","volume":"11","author":"Faccioli","year":"2022","journal-title":"J Clin Med"},{"key":"R66-20251112","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jtcvs.2018.04.110","article-title":"Residual pulmonary hypertension after pulmonary endarterectomy: a meta-analysis.","volume":"156","author":"Hsieh","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R67-20251112","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.athoracsur.2019.03.100","article-title":"Predictors of outcomes after surgery for chronic thromboembolic pulmonary hypertension.","volume":"108","author":"Sakurai","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R68-20251112","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1055\/s-0043-1770123","article-title":"Perioperative management in pulmonary endarterectomy.","volume":"44","author":"Jenkins","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"R69-20251112","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1161\/CIR.0000000000001197","article-title":"Status and future directions for balloon pulmonary angioplasty in chronic thromboembolic pulmonary disease with and without pulmonary hypertension: a scientific statement from the American Heart Association.","volume":"149","author":"Aggarwal","year":"2024","journal-title":"Circulation"},{"key":"R70-20251112","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00270-022-03323-8","article-title":"Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.","volume":"46","author":"Kennedy","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R71-20251112","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"R72-20251112","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S2213-2600(22)00214-4","article-title":"Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.","volume":"10","author":"Ja\u00efs","year":"2022","journal-title":"Lancet Respir Med"},{"key":"R73-20251112","doi-asserted-by":"crossref","first-page":"108154","DOI":"10.1016\/j.rmed.2025.108154","article-title":"Balloon pulmonary angioplasty and riociguat in the management of chronic thromboembolic pulmonary hypertension: a systematic review.","volume":"244","author":"Ara\u00fajo","year":"2025","journal-title":"Respir Med"},{"key":"R74-20251112","doi-asserted-by":"crossref","first-page":"e014785","DOI":"10.1161\/CIRCINTERVENTIONS.124.014785","article-title":"Effect of balloon pulmonary angioplasty and riociguat on right ventricular afterload and function in CTEPH: insights from the RACE trial.","volume":"18","author":"Gerges","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"key":"R75-20251112","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1161\/CIR.0000000000000560","article-title":"Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association.","volume":"137","author":"Konstam","year":"2018","journal-title":"Circulation"},{"key":"R76-20251112","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ahj.2007.02.019","article-title":"Atrial septostomy improves survival in select patients with pulmonary hypertension.","volume":"153","author":"Law","year":"2007","journal-title":"Am Heart J"},{"key":"R77-20251112","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s40001-025-02776-0","article-title":"Atrial septostomy in the management of pulmonary arterial hypertension: past, present, and future.","volume":"30","author":"Dong","year":"2025","journal-title":"Eur J Med Res"},{"key":"R78-20251112","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.chest.2019.03.003","article-title":"Use of balloon atrial septostomy in patients with advanced pulmonary arterial hypertension: a systematic review and meta-analysis.","volume":"156","author":"Khan","year":"2019","journal-title":"Chest"},{"key":"R79-20251112","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jcin.2022.09.013","article-title":"Pulmonary artery denervation for pulmonary arterial hypertension: a sham-controlled randomized PADN-CFDA trial.","volume":"15","author":"Zhang","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"R80-20251112","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.healun.2023.03.015","article-title":"Treatment effects of pulmonary artery denervation for pulmonary arterial hypertension stratified by REVEAL risk score: Results from PADN-CFDA trial.","volume":"42","author":"Zhang","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"R81-20251112","doi-asserted-by":"crossref","first-page":"133078","DOI":"10.1016\/j.ijcard.2025.133078","article-title":"Pulmonary artery denervation in pulmonary hypertension: a comprehensive meta-analysis.","volume":"427","author":"Abouzid","year":"2025","journal-title":"Int J Cardiol"},{"key":"R82-20251112","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.chest.2023.04.047","article-title":"Lung transplantation for pulmonary arterial hypertension.","volume":"164","author":"Kolaitis","year":"2023","journal-title":"Chest"},{"key":"R83-20251112","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.21037\/jtd-2021-20","article-title":"Lung transplantation for pulmonary hypertension.","volume":"13","author":"Hwalek","year":"2021","journal-title":"J Thorac Dis"},{"key":"R84-20251112","doi-asserted-by":"crossref","first-page":"2401193","DOI":"10.1183\/13993003.01193-2024","article-title":"Transplantation, bridging, and support technologies in pulmonary hypertension.","volume":"64","author":"Savale","year":"2024","journal-title":"Eur Respir J"},{"key":"R85-20251112","doi-asserted-by":"crossref","first-page":"e00080","DOI":"10.1161\/HHF.0000000000000080","article-title":"Pulmonary hypertension in congenital heart disease: a scientific statement from the American Heart Association.","volume":"16","author":"Jone","year":"2023","journal-title":"Circ Heart Fail"},{"key":"R86-20251112","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0003-4975(01)03082-X","article-title":"Lung transplantation for pulmonary vascular disease.","volume":"73","author":"Mendeloff","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"R87-20251112","doi-asserted-by":"crossref","first-page":"e13586","DOI":"10.1111\/ctr.13586","article-title":"Lung transplantation in patients with severe pulmonary hypertension-Focus on right ventricular remodelling.","volume":"33","author":"Schuba","year":"2019","journal-title":"Clin Transplant"},{"key":"R88-20251112","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jtcvs.2011.08.055","article-title":"Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience.","volume":"143","author":"de Perrot","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R89-20251112","doi-asserted-by":"crossref","first-page":"154120","DOI":"10.1016\/j.jcrc.2022.154120","article-title":"Survival and left ventricular dysfunction post lung transplantation for pulmonary arterial hypertension.","volume":"72","author":"Otto","year":"2022","journal-title":"J Crit Care"},{"key":"R90-20251112","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.transproceed.2019.01.024","article-title":"Risk analysis of perioperative death in lung transplant patients with severe idiopathic pulmonary hypertension.","volume":"51","author":"Zhu","year":"2019","journal-title":"Transplant Proc"},{"key":"R91-20251112","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/ejcts\/ezx212","article-title":"Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome.","volume":"53","author":"Moser","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"R92-20251112","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1007\/s10067-022-06446-y","article-title":"Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.","volume":"42","author":"Cansu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R93-20251112","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00296-025-05845-z","article-title":"Prevalence, molecular mechanisms and diagnostic approaches to pulmonary arterial hypertension in connective tissue diseases.","volume":"45","author":"Grygiel-G\u00f3rniak","year":"2025","journal-title":"Rheumatol Int"},{"key":"R94-20251112","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1093\/rheumatology\/kead360","article-title":"Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: a COMPERA analysis.","volume":"63","author":"Distler","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R95-20251112","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.14162","article-title":"Diagnostic criteria, severity classification and guidelines of systemic sclerosis.","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol"},{"key":"R96-20251112","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R97-20251112","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/art.41732","article-title":"Performance of the DETECT algorithm for pulmonary hypertension screening in a systemic sclerosis cohort.","volume":"73","author":"Young","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R98-20251112","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","article-title":"A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis.","volume":"17","author":"Hao","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R99-20251112","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/imj.16468","article-title":"Predictive accuracy of the ASIG algorithm in a prospective systemic sclerosis cohort undergoing annual screening for pulmonary arterial hypertension.","volume":"54","author":"Brown","year":"2024","journal-title":"Intern Med J"},{"key":"R100-20251112","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.","volume":"76","author":"Coghlan","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R101-20251112","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2019-216274","article-title":"Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.","volume":"79","author":"Kuwana","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R102-20251112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis.","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R103-20251112","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3390\/ph16091252","article-title":"Recent advances in the treatment of pulmonary arterial hypertension associated with connective tissue diseases.","volume":"16","author":"Smukowska-Gorynia","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R104-20251112","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/1570161120666220811150853","article-title":"Targeted therapies in patients with pulmonary arterial hypertension due to congenital heart disease.","volume":"20","author":"Mares","year":"2022","journal-title":"Curr Vasc Pharmacol"},{"key":"R105-20251112","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.amjcard.2025.07.035","article-title":"Pharmacological treatment practices for patients with congenital heart disease and pulmonary hypertension in Japan: insights from the Japanese Association of Congenital Heart Disease Registry (JACPHR).","volume":"257","author":"Ishii","year":"2025","journal-title":"Am J Cardiol"},{"key":"R106-20251112","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.clinthera.2023.07.001","article-title":"Recent advances in pediatric pulmonary hypertension: implications for diagnosis and treatment.","volume":"45","author":"Sullivan","year":"2023","journal-title":"Clin Ther"},{"key":"R107-20251112","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s00431-025-06099-4","article-title":"Pulmonary hypertension in pediatrics: from clinical suspicion to management.","volume":"184","author":"Wacker","year":"2025","journal-title":"Eur J Pediatr"},{"key":"R108-20251112","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.jacc.2018.08.1029","article-title":"2018 AHA\/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"73","author":"Stout","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R109-20251112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1164\/rccm.202410-1901ST","article-title":"Interventional strategies for children with progressive pulmonary hypertension despite optimal therapy: an official American Thoracic Society clinical practice guideline.","volume":"211","author":"Hayes","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"R110-20251112","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacc.2021.05.039","article-title":"Pulmonary-to-systemic arterial shunt to treat children with severe pulmonary hypertension.","volume":"78","author":"Grady","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R111-20251112","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/1471-0528.17474","article-title":"Management and outcomes of pulmonary artery hypertension and Eisenmenger syndrome during pregnancy: a prospective observational cohort study.","volume":"130","author":"Jha","year":"2023","journal-title":"BJOG"},{"key":"R112-20251112","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R113-20251112","doi-asserted-by":"crossref","first-page":"e000086","DOI":"10.1161\/HHF.0000000000000086","article-title":"Clinical management and transplant considerations in pediatric pulmonary hypertension due to left heart disease: a scientific statement from the American Heart Association.","volume":"18","author":"Hopper","year":"2025","journal-title":"Circ Heart Fail"},{"key":"R114-20251112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.09.043","article-title":"Pulmonary vasodilator therapies are of no benefit in pulmonary hypertension due to left heart disease: a meta-analysis.","volume":"273","author":"Cao","year":"2018","journal-title":"Int J Cardiol"},{"key":"R115-20251112","doi-asserted-by":"crossref","first-page":"e0204610","DOI":"10.1371\/journal.pone.0204610","article-title":"Pulmonary hypertension-targeted therapies in heart failure: a systematic review and meta-analysis.","volume":"13","author":"Guay","year":"2018","journal-title":"PLoS One"},{"key":"R116-20251112","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/MCP.0000000000000694","article-title":"Clinical trials in group 3 pulmonary hypertension.","volume":"26","author":"Harder","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"R117-20251112","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease.","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"R118-20251112","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE Trial.","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"R119-20251112","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1164\/rccm.202412-2371OC","article-title":"Hemodynamics and phosphodiesterase-5 inhibitor treatment associated with survival in ILD-PH: a PVRI Godeep meta-registry analysis.","volume":"211","author":"Yogeswaran","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"R120-20251112","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a Bayesian retrospective observational cohort study.","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"key":"R121-20251112","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/CIR.0000000000000329","article-title":"Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society.","volume":"132","author":"Abman","year":"2015","journal-title":"Circulation"},{"key":"R122-20251112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jpeds.2018.09.067","article-title":"Sildenafil use in children with pulmonary hypertension.","volume":"205","author":"Cohen","year":"2019","journal-title":"J Pediatr"},{"key":"R123-20251112","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/s12887-020-02453-7","article-title":"Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study.","volume":"20","author":"Schneider","year":"2020","journal-title":"BMC Pediatr"},{"key":"R124-20251112","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.124.068610","article-title":"Worldwide CTEPH registry: long-term outcomes with pulmonary endarterectomy, balloon pulmonary angioplasty, and medical therapy.","volume":"150","author":"Delcroix","year":"2024","journal-title":"Circulation"},{"key":"R125-20251112","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ijcard.2015.11.039","article-title":"Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective.","volume":"203","author":"Escribano-Sub\u00edas","year":"2016","journal-title":"Int J Cardiol"},{"key":"R126-20251112","doi-asserted-by":"crossref","first-page":"e12001","DOI":"10.1002\/pul2.12001","article-title":"Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.","volume":"12","author":"Appenzeller","year":"2022","journal-title":"Pulm Circ"},{"key":"R127-20251112","doi-asserted-by":"crossref","first-page":"2045894019855611","DOI":"10.1177\/2045894019855611","article-title":"Current organization of specialist pulmonary hypertension clinics: results of an international survey.","volume":"9","author":"Doyle-Cox","year":"2019","journal-title":"Pulm Circ"},{"key":"R128-20251112","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.106.618397","article-title":"Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.","volume":"114","author":"Mereles","year":"2006","journal-title":"Circulation"},{"key":"R129-20251112","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1183\/09031936.00123711","article-title":"Safety and efficacy of exercise training in various forms of pulmonary hypertension.","volume":"40","author":"Gr\u00fcnig","year":"2012","journal-title":"Eur Respir J"},{"key":"R130-20251112","doi-asserted-by":"crossref","first-page":"e12247","DOI":"10.1002\/pul2.12247","article-title":"Patient perspectives on pulmonary hypertension in the United States: burdens, expectations, and goals.","volume":"13","author":"Braley","year":"2023","journal-title":"Pulm Circ"},{"key":"R131-20251112","doi-asserted-by":"crossref","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","article-title":"COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.","volume":"60","author":"Hoeper","year":"2022","journal-title":"Eur Respir J"},{"key":"R132-20251112","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.chest.2019.02.004","article-title":"Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC\/ERS-based risk assessment strategies.","volume":"156","author":"Benza","year":"2019","journal-title":"Chest"},{"key":"R133-20251112","doi-asserted-by":"crossref","first-page":"107066","DOI":"10.1016\/j.rmed.2022.107066","article-title":"Palliative care referral patterns in pulmonary arterial hypertension: Insights from the PHAR registry.","volume":"206","author":"Rohlfing","year":"2023","journal-title":"Respir Med"},{"key":"R134-20251112","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.chest.2020.07.079","article-title":"Inpatient palliative care use in patients with pulmonary arterial hypertension: temporal trends, predictors, and outcomes.","volume":"158","author":"Anand","year":"2020","journal-title":"Chest"},{"key":"R135-20251112","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.healun.2012.08.010","article-title":"Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: results from a cross-sectional patient survey.","volume":"31","author":"Swetz","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"R136-20251112","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/MCP.0000000000001195","article-title":"Precision medicine in pulmonary hypertension: how close are we today?","volume":"31","author":"Maron","year":"2025","journal-title":"Curr Opin Pulm Med"},{"key":"R137-20251112","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S2213-2600(24)00425-9","article-title":"Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients.","volume":"13","author":"Rahaghi","year":"2025","journal-title":"Lancet Respir Med"},{"key":"R138-20251112","doi-asserted-by":"crossref","first-page":"2201232","DOI":"10.1183\/13993003.01232-2022","article-title":"Cytokines as prognostic biomarkers in pulmonary arterial hypertension.","volume":"61","author":"Boucly","year":"2023","journal-title":"Eur Respir J"},{"key":"R139-20251112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12931-021-01716-w","article-title":"Plasma markers in pulmonary hypertension subgroups correlate with patient survival.","volume":"22","author":"Koudstaal","year":"2021","journal-title":"Respir Res"},{"key":"R140-20251112","doi-asserted-by":"crossref","first-page":"e032888","DOI":"10.1161\/JAHA.123.032888","article-title":"Prognostic significance of proteomics-discovered circulating inflammatory biomarkers in patients with pulmonary arterial hypertension.","volume":"13","author":"Yokokawa","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R141-20251112","doi-asserted-by":"crossref","first-page":"2401370","DOI":"10.1183\/13993003.01370-2024","article-title":"Genetics and precision genomics approaches to pulmonary hypertension.","volume":"64","author":"Austin","year":"2024","journal-title":"Eur Respir J"},{"key":"R142-20251112","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/ijms22031179","article-title":"Genetic delivery and gene therapy in pulmonary hypertension.","volume":"22","author":"Rai","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:00:51Z","timestamp":1762923651000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":141,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001121","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}